BeOne Medicines Ltd
ONCHealthcare|Biotechnology|Switzerland
$298.70
-4.13 (-1.36%)
Tangible Book
$42.27
Graham Number
$97.57
Clinical Trials (112)
| Trial | Conditions | Phase | Status | Enrollment | Design | Drug |
|---|---|---|---|---|---|---|
| NCT07169331 A Study to Evaluate the Efficacy and Safety of Zanubrutinib in Chinese Adults With Treatment-Naive Waldenström Macroglobulinemia | Waldenström's Macroglobulinemia | P4 | Recruiting | 18 | Open-label | Zanubrutinib |
| NCT05152147 A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal Cancers | Gastric Neoplasms, Gastroesophageal Adenocarcinoma | P3 | Active | 920 | RCT, Open-label | Zanidatamab, Tislelizumab, Trastuzumab, Capecitabine, Oxaliplatin, Cisplatin, 5-Fluorouracil |
| NCT06970743 A Study of BGB-16673 Compared to Investigator's Choice in Participants With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Covalent Bruton Tyrosine Kinase (BTK) Inhibitors | Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | P3 | Active | 153 | RCT, Open-label | BGB-16673, Bendamustine, Rituximab, Methylprednisolone |
| NCT07492641 BGB-43395 Plus Letrozole Versus CDK4/6i Plus Letrozole for Patients With Advanced or Metastatic HR+/HER2- Breast Cancer Who Have Not Received Prior Treatment for Advanced or Metastatic Disease | HR+/HER2- Breast Cancer | P3 | Recruiting | 1,056 | RCT, Open-label | BGB-43395, Letrozole, Abemaciclib, Palbociclib, Ribociclib |
| NCT03519230 Maintenance Treatment With BGB-290 Versus Placebo in Participants With Platinum-sensitive Recurrent Ovarian Cancer | Ovarian Cancer | P3 | Active | 224 | RCT, Double-blind | Pamiparib capsule, Placebo capsule |
| NCT04379635 Comparing the Efficacy and Safety of a New Additional Treatment With Tislelizumab in Non-Small Cell Lung Cancer (NSCLC) | Non Small Cell Lung Cancer | P3 | Active | 453 | RCT, Double-blind | Tislelizumab, Cisplatin injection, Paclitaxel injection, Pemetrexed Disodium, Placebos, Carboplatin |
| NCT06943872 A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL) | Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | P3 | Recruiting | 630 | RCT, Open-label | Sonrotoclax, Obinutuzumab, Rituximab, Venetoclax |
| NCT04002297 A Study to Investigate the Efficacy of Zanubrutinib Plus Rituximab Compared With Bendamustine Plus Rituximab in Adults With Previously Untreated Mantle Cell Lymphoma Who Are Ineligible for Stem Cell Transplantation | Mantle Cell Lymphoma; Non-Hodgkin Lymphoma | P3 | Active | 510 | RCT, Open-label | zanubrutinib, bendamustine, rituximab |
| NCT06073821 Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Participants With Chronic Lymphocytic Leukemia (CLL) | CLL | P3 | Active | 652 | RCT, Open-label | Sonrotoclax, Zanubrutinib, Venetoclax, Obinutuzumab |
| NCT07277231 A Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Adults With Previously Untreated Chronic Lymphocytic Leukemia | Chronic Lymphocytic Leukemia | P3 | Recruiting | 500 | RCT, Open-label | Sonrotoclax, Zanubrutinib, Acalabrutinib, Venetoclax |
| NCT05100862 A Study of Zanubrutinib Plus Anti-CD20 Versus Lenalidomide Plus Rituximab in Participants With Relapsed/Refractory Follicular or Marginal Zone Lymphoma | Relapsed/Refractory Follicular Lymphoma, Marginal Zone Lymphoma | P3 | Recruiting | 780 | RCT, Open-label | Zanubrutinib, Rituximab, Lenalidomide, Obinutuzumab |
| NCT03967977 Study of Tislelizumab in Combination With Chemotherapy Compared to Chemotherapy Alone for Participants With Urothelial Carcinoma | Urothelial Carcinoma | P3 | Active | 420 | RCT, Double-blind | Tislelizumab, Placebo, Cisplatin, Gemcitabine Hydrochloride, Carboplatin |
| NCT06742996 A Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubrutinib Compared With Placebo Plus Zanubrutinib in Adults With Relapsed/Refractory Mantle Cell Lymphoma (CELESTIAL-RRMCL) | Mantle Cell Lymphoma, B Cell Lymphoma | P3 | Recruiting | 300 | RCT, Double-blind | Sonrotoclax, Zanubrutinib, Placebo |
| NCT06846671 A Study of BGB-16673 Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both Bruton Tyrosine Kinase (BTK) and B-cell Leukemia/Lymphoma 2 Protein (BCL2) Inhibitors | CLL, Chronic Lymphocytic Leukemia | P3 | Recruiting | 250 | RCT, Open-label | BGB-16673, Bendamustine, Idelalisib, Rituximab, Venetoclax |
| NCT04170283 Long-term Extension Study of Zanubrutinib (BGB-3111) Regimens in Participants With B-cell Malignancies | B-cell Malignancies | P3 | Active | 955 | Open-label | Zanubrutinib, Tislelizumab |
| NCT06973187 A Study to Evaluate the Safety and Efficacy of BGB-16673 Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | P3 | Recruiting | 500 | RCT, Open-label | BGB-16673, Pirtobrutinib |
| NCT07043400 A Study to Investigate Tislelizumab Administered as Subcutaneous Injection Versus Intravenous Infusion Plus Chemotherapy in Patients With Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma | Metastatic Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma | P3 | Recruiting | 351 | RCT, Open-label | Subcutaneous Tislelizumab, Intravenous Tislelizumab, Cisplatin, Leucovorin, 5-fluorouracil (5-FU), Oxaliplatin, Capecitabine |
| NCT05707377 A Study to Examine the Efficacy and Safety of Zanubrutinib Given to Adults With Primary Membranous Nephropathy | Primary Membranous Nephropathy | P2P3 | Active | 178 | RCT, Open-label | Zanubrutinib, Tacrolimus |
| NCT03336333 A Study Comparing Zanubrutinib With Bendamustine Plus Rituximab in Participants With Previously Untreated CLL or SLL | Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | P3 | Active | 590 | RCT, Open-label | Zanubrutinib, Bendamustine, Rituximab, Venetoclax |
| NCT06093061 Tislelizumab and Metronomic Capecitabine as Maintenance in High-risk Locoregionally-advanced Nasopharyngeal Carcinoma | Nasopharyngeal Carcinoma | P2 | Recruiting | 53 | Open-label | — |
| NCT05873712 Zanubrutinib and Lisocabtagene Maraleucel for the Treatment of Richter's Syndrome | Recurrent Transformed Chronic Lymphocytic Leukemia, Refractory Transformed Chronic Lymphocytic Leukemia | P2 | Recruiting | 24 | Open-label | Cyclophosphamide, Fludarabine, Lisocabtagene Maraleucel, Zanubrutinib |
| NCT06350318 Rituximab and Zanubrutinib in Patients With Indolent B-cell Lymphomas | Follicular Lymphoma, Marginal Zone Lymphoma | P2 | Recruiting | 43 | Open-label | Zanubrutinib, Rituximab |
| NCT03824483 Study of Zanubrutinib, Obinutuzumab, and Venetoclax in Patients With Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL) | Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Leukemia (SLL) | P2 | Recruiting | 230 | Open-label | Zanubrutinib, Obinutuzumab, Venetoclax |
| NCT05609370 A Study Investigating the Efficacy and Safety of Alcestobart (LBL-007) Plus Tislelizumab in Combination With Bevacizumab Plus Fluoropyrimidine Versus Bevacizumab Plus Fluoropyrimidine in Participants With Unresectable or Metastatic Colorectal Cancer | Unresectable or Metastatic Microsatellite Stable/Mismatch Repair Proficient Colorectal Cancer | P1P2 | Active | 113 | RCT, Open-label | Alcestobart, Tislelizumab, Bevacizumab or Bevacizumab biosimilar, Fluoropyrimidine (FP) |
| NCT04973605 A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma | Relapsed/Refractory Multiple Myeloma | P1P2 | Recruiting | 246 | RCT, Open-label | Sonrotoclax, Dexamethasone, Carfilzomib, Daratumumab, Pomalidomide |
| NCT03736889 Tislelizumab (Anti-Programmed Cell Death Protein-1 (PD-1) Antibody) in MSI-H or dMMR Solid Tumors | MSI-H/dMMR Solid Tumors | P2 | Recruiting | 200 | Open-label | Tislelizumab (BGB-A317) |
| NCT05294731 Treatment of Chinese Participants With B-Cell Malignancies With BGB-16673, a Bruton Tyrosine Kinase-Targeted Protein-Degrader | B-cell Malignancy, Non-Hodgkin Lymphoma | P1P2 | Recruiting | 146 | RCT, Open-label | BGB-16673 |
| NCT06697184 A Study to Investigate the Safety of Novel Dose Ramp-up Schedule(s) When Initiating Sonrotoclax in Participants Treated for Blood Cancers. | Chronic Lymphocytic Leukemia, CLL | P1P2 | Recruiting | 258 | Open-label | Sonrotoclax, Zanubrutinib |
| NCT06849713 Zanubrutinib, Obinutuzumab, and Sonrotoclax in Previously Untreated Patients With CLL or SLL | Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma (SLL) | P2 | Recruiting | 40 | Open-label | Zanubrutinib, Sonrotoclax, Obinutuzumab |
| NCT07339488 Intestinal Low-Dose Radiotherapy Plus Immunochemotherapy for Conversion of Borderline Resectable/Unresectable Esophageal Squamous Cell Carcinoma | Borderline Resectable Carcinoma, Unresectable Cancer | P2 | Recruiting | 43 | Open-label | PD-1/PD-L1 inhibitors, Chemotherapy |
| NCT05661955 A Study to Investigate the Antitumor Activity, Safety, Tolerability, and Pharmacokinetics of BGB-A445 in Combination With Tislelizumab in Participants With Select Advanced Solid Tumors. | Urothelial Carcinoma, Renal Cell Carcinoma | P1P2 | Active | 113 | Open-label | BGB-A445, Tislelizumab |
| NCT05006716 A Dose-Escalation and Expansion Study of BGB-16673 in Participants With B-Cell Malignancies | B-cell Malignancy, Marginal Zone Lymphoma | P1P2 | Recruiting | 645 | RCT, Open-label | BGB-16673 |
| NCT07554521 A Study to Evaluate Efficacy and Safety of Tislelizumab Plus Chemotherapy for Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Adenocarcinoma and Esophageal Squamous Cell Carcinoma in Racial and Ethnic Minority Patients in the United States | Advanced Unresectable Gastric Adenocarcinoma, Esophageal Squamous Cell Carcinoma | P2 | Recruiting | 30 | Open-label | Tislelizumab, Capecitabine, 5-fluorouracil (5-FU), Oxaliplatin, Leucovorin |
| NCT06561347 Zanubrutinib, Bendamustine, Rituximab Prev. Untreated WM | Waldenstrom Macroglobulinemia | P2 | Recruiting | 56 | Open-label | Zanubrutinib, Bendamustine, Rituximab |
| NCT04521231 A Study of Subcutaneous Blinatumomab Administration in Participants With R/R and MRD+ B-ALL | B Cell Precursor Acute Lymphoblastic Leukemia | P1P2 | Active | 181 | Open-label | Blinatumomab |
| NCT04771130 A Study of BGB-11417 in Participants With Myeloid Malignancies | Acute Myeloid Leukemia, Myelodysplastic Syndromes | P1P2 | Recruiting | 260 | Open-label | BGB-11417, Azacitidine, Posaconazole, BGB-11417, BGB-11417 |
| NCT05479994 Study of BGB-11417 in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | Leukemia, Lymphoma | P2 | Active | 100 | Open-label | BGB-11417 |
| NCT07134088 A Study of Subcutaneous Blinatumomab in Children With R/R and and MRD+ B-Cell Precursor Acute Lymphoblastic Leukemia | Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia, Minimal Residual Disease + B-Cell Acute Lymphoblastic Leukemia | P1P2 | Active | 104 | Open-label | Blinatumomab |
| NCT05635708 A Study of Tislelizumab in Combination With Investigational Agents in Participants With Non-Small Cell Lung Cancer | Non-small Cell Lung Cancer, Metastatic Non-small Cell Lung Cancer | P2 | Active | 400 | RCT, Open-label | Tislelizumab, BGB-A445, LBL-007, Carboplatin, Cisplatin, pemetrexed, Paclitaxel, Nab paclitaxel, BGB-15025 |
| NCT05952037 A Study to Investigate Efficacy and Safety of BCL2 Inhibitor Sonrotoclax as Monotherapy and in Combination With Zanubrutinib in Adults With Waldenström Macroglobulinemia | Waldenstrom Macroglobulinemia, Waldenstrom's Macroglobulinemia Recurrent | P2 | Active | 114 | Open-label | Sonrotoclax, Zanubrutinib |
| NCT06634589 A Study to Investigate Safety and Effectiveness of BGB-16673 in Combination With Other Agents in Participants With Relapsed or Refractory B-Cell Malignancies | B-cell Malignancy, Relapsed Cancer | P1P2 | Recruiting | 80 | Open-label | BGB-16673, Sonrotoclax, Zanubrutinib, Mosunetuzumab, Glofitamab, Obinutuzumab |
| NCT06637501 A Study to Investigate Sonrotoclax Combined With Zanubrutinib Versus Zanubrutinib Alone in Participants With Previously Untreated Chronic Lymphocytic Leukemia | Chronic Lymphocytic Leukemia | P2 | Active | 94 | RCT, Open-label | Sonrotoclax, Zanubrutinib |
| NCT06839053 Sonrotoclax, Rituximab, and Zanubrutinib in Treating Participants With Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, and Mantle Cell Lymphoma | Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma | P2 | Recruiting | 30 | Open-label | Rituximab, Sonrotoclax, Zanubrutinib |
| NCT07341191 Sonrotoclax Plus Zanubrutinib in Patients With Relapsed/Refractory Mantle Cell Lymphoma Planned for Standard of Care CAR-T Cell Therapy | Mantle Cell Lymphoma | P2 | Recruiting | 40 | Open-label | Zanubrutinib, Sonrotoclax, CAR-T Cell Therapy |
| NCT06596473 A Study of BG-C477 in Participants With Advanced Solid Tumors | Advanced Solid Tumors | P1 | Recruiting | 310 | Open-label | BG-C477, Tislelizumab, Chemotherapy |
| NCT06257264 A Study to Examine the Safety of Different Doses of BG-68501 Given to Participants With Advanced-Stage Tumors | Breast Cancer, Small Cell Lung Cancer | P1 | Active | 103 | Open-label | BG-68501, Fulvestrant, BGB-43395 |
| NCT06427941 A Phase 1 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid Tumors | Metastatic Hepatocellular Carcinoma, Local Advanced Hepatocellular Carcinoma | P1 | Recruiting | 392 | Open-label | BGB-B2033, Tislelizumab, Bevacizumab |
| NCT07412691 A Study to Evaluate the Safety of BG-A3004 in Healthy Participants and Patients With Immune-Mediated Skin Diseases | Skin Diseases | P1 | Recruiting | 98 | RCT, Double-blind | BG-A3004, Placebo |
| NCT06120283 BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors | Advanced Solid Tumor, Advanced Breast Cancer | P1 | Recruiting | 399 | Open-label | BGB-43395, Fulvestrant, Letrozole, Elacestrant, Anti-Diarrheal Agent |
| NCT07671339 A Study of ELI-002 7P, With or Without Tislelizumab, in People With Pancreatic Cancer | Pancreatic Cancer | P1 | Recruiting | 20 | RCT, Open-label | ELI-002 7P, Tislelizumab, mFOLFIRINOX |
| NCT05981703 A Study Investigating BGB-26808 Alone or in Combination With Tislelizumab in Participants With Advanced Solid Tumors | Advanced Solid Tumor, Solid Tumor | P1 | Recruiting | 217 | RCT, Open-label | BGB-26808, Tislelizumab, Chemotherapy |
| NCT06756932 BGB-21447 (Bcl-2 Inhibitor) Combinations for Adults With Hormone-Receptor Positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Metastatic Breast Cancer | Hormone-receptor-positive Breast Cancer, HER2-negative Breast Cancer | P1 | Recruiting | 120 | Open-label | BGB-21447, Fulvestrant, BGB-43395 |
| NCT04883957 Study of BGB-11417 in Adult Participants With Mature B-cell Malignancies | Mature B-cell Malignancies | P1 | Active | 64 | Open-label | BGB-11417 |
| NCT05828589 A Study of BGB-21447, a Bcl-2 Inhibitor, in Mature B-Cell Malignancies | Relapsed Non-Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma | P1 | Active | 112 | RCT, Open-label | BGB-21447 |
| NCT06625593 A First-in-Human (FIH) Study of BG-C137, an Anti-Fibroblast Growth Factor Receptor 2b (FGFR2b) Antibody Drug Conjugate, in Participants With Advanced Solid Tumors | Advanced Solid Tumor | P1 | Recruiting | 168 | Open-label | BG-C137, Anticancer Agents |
| NCT06589596 An Investigational Study of BGB-58067 As a Single Agent and in Combination With Anticancer Agents in Participants With Advanced Solid Tumors | Advanced Solid Tumor | P1 | Recruiting | 525 | Open-label | BGB-58067, BG-89894, Standard of Care Therapy |
| NCT06598306 Subcutaneous Tarlatamab in Participants With Extensive Stage Small Cell Lung Cancer (DeLLphi-308) | Extensive Stage Small Cell Lung Cancer | P1 | Recruiting | 220 | Open-label | Tarlatamab |
| NCT07590102 A Study to Investigate the Effect of the CYP3A Inducer Phenytoin and the CYP3A Inhibitor Itraconazole on the Pharmacokinetics of BGB-58067 in Healthy Participants | Healthy Volunteers | P1 | Recruiting | 30 | Open-label | BGB-58067, Phenytoin, Itraconazole |
| NCT06803680 A Study of BGB-B455 in Adults With Advanced or Metastatic Solid Tumors | Advanced Solid Tumor, Metastatic Solid Tumor | P1 | Recruiting | 90 | Open-label | BGB-B455, Chemotherapy |
| NCT06233942 Phase 1a/1b First-in-Human Study of BG-C9074 Alone and in Combination With Other Anticancer Therapies in Patients With Advanced Solid Tumors | Advanced Solid Tumor | P1 | Recruiting | 308 | Open-label | BG-C9074, Tislelizumab, Bevacizumab |
| NCT07628881 A Study to Investigate the Relative Bioavailability and Food Effect of Tablet for Oral Suspension of Sonrotoclax in Healthy Adults | Healthy Volunteers | P1 | Recruiting | 12 | RCT, Open-label | Sonrotoclax Tablet for Oral Suspension, Sonrotoclax Tablet |
| NCT06598800 Study of BG-T187 Alone and in Combination With Other Therapeutic Agents in Participants With Advanced Solid Tumors | Advanced Solid Tumor | P1 | Recruiting | 153 | Open-label | Drug: BG-T187, Other Therapeutic Agents |
| NCT04277637 Study of Bcl-2 Inhibitor Sonrotoclax (BGB-11417) in Participants With Mature B-Cell Malignancies | Mature B-Cell Malignancies | P1 | Active | 437 | Open-label | Sonrotoclax, Zanubrutinib, Obinutuzumab |
| NCT07414836 A First-in-Human Study of BG-C0979 in Adults With Advanced Solid Tumors | Advanced Solid Tumor | P1 | Recruiting | 84 | Open-label | BG-C0979, Tislelizumab |
| NCT07226349 A Study of BG-75098 Alone and in Combination With Other Agents in Adults With Advanced Solid Tumors | Advanced Solid Tumor | P1 | Recruiting | 105 | Open-label | BG-75098, BGB-43395, Fulvestrant |
| NCT07222267 An Investigational Study of BG-75202 Alone and in Combination With Other Therapeutic Agents in Adults With Advanced Solid Tumors | Breast Cancer, Advanced Solid Tumor | P1 | Recruiting | 86 | Open-label | BG-75202, CDK4 Inhibitor, Estrogen Receptor Antagonist, Aromatase Inhibitor |
| NCT07619287 An Investigational Study of BG-75202 Alone and in Combination With Other Agents in Patients With Myeloid Malignancies | Myeloid Malignancy | P1 | Recruiting | 118 | Open-label | BG-75202, Hypomethylation Agent (HMA) |
| NCT07181681 A First-in-Human Study of BG-C0902 Alone and in Combination With Other Therapeutic Agents in Patients With Advanced Solid Tumors | Solid Tumors, Advanced Solid Tumor | P1 | Recruiting | 63 | Open-label | BG-C0902 |
| NCT07485049 BGB-58067 in Newly Diagnosed Glioblastoma Patients With MTAP-Deleted Tumors | Glioblastoma (GBM) | Early P1 | Recruiting | 78 | Open-label | BGB-58067 |
| NCT05326308 Zanubrutinib in Patients With Waldenström's Macroglobulinemia, Chronic Lymphocytic Leukemia, Marginal Zone Lymphoma and Follicular Lymphoma | Waldenström's Macroglobulinemia, Chronic Lymphocytic Leukemia | Recruiting | 705 | — | Zanubrutinib, Obinutuzumab | |
| NCT07510724 Real-World Data on the Treatment of Lung Cancer Patients With the Immune-Checkpoint Inhibitor Tislelizumab | Small Cell Lung Cancer (SCLC), Non-Small Cell Lung Cancer (NSCLC) | Recruiting | 240 | — | — | |
| NCT05640102 Observational Study Evaluating the Efficacy and Safety of Zanubrutinib in Participants With Waldenström Macroglobulinemia | Waldenstrom Macroglobulinemia | Recruiting | 111 | — | Zanubrutinib | |
| NCT07652736 A Study to Investigate Treatment Patterns and Effectiveness of Tislelizumab in European Patients With Resectable or Advanced Non-Small Cell Lung Cancer (NSCLC) and Small Cell Lung Cancer (SCLC) | Advanced Non-Small Cell Lung Cancer, Extensive-Stage Small Cell Lung Cancer | Recruiting | 440 | — | Tislelizumab | |
| NCT04486391 Tislelizumab Monotherapy Versus Salvage Chemotherapy for Relapsed/Refractory Classical Hodgkin Lymphoma | Classical Hodgkin Lymphoma | P3 | Terminated | 3 | RCT, Open-label | Tislelizumab, Salvage Chemotherapy |
| NCT04164199 Study of Tislelizumab, Pamiparib, and Other Investigational Agents in Participants With Advanced Malignancies | Advanced Malignancies | P3 | Completed | 404 | Open-label | Tislelizumab, Pamiparib, Temozolomide, Sitravatinib, Ociperlimab, BAT1706, Fruquintinib, BGB-15025, Zanidatamab, BGB-A445, Surzebiclimab, Lenvatinib, LBL-007 |
| NCT03957590 A Study to Investigate Tislelizumab (BGB-A317) Versus Placebo in Combination With Concurrent Chemoradiotherapy in Participants With Localized Esophageal Squamous Cell Carcinoma | Esophageal Squamous Cell Carcinoma (ESCC) | P3 | Completed | 370 | RCT, Double-blind | Tislelizumab, Placebo, Paclitaxel, Cisplatin |
| NCT04746924 A Study of Ociperlimab With Tislelizumab Compared to Pembrolizumab in Participants With Untreated Lung Cancer | Non-small Cell Lung Cancer, NSCLC | P3 | Terminated | 669 | RCT, Double-blind | Tislelizumab, Ociperlimab, Pembrolizumab, Placebo |
| NCT04911517 Neoadjuvant Chemoradiotherapy Plus Tislelizumab Followed by TME for LARC. | Colorectal Neoplasms | P2 | Unknown | 50 | Open-label | — |
| NCT04466891 A Study of ZW25 (Zanidatamab) in Subjects With Advanced or Metastatic HER2-Amplified Biliary Tract Cancers | HER2-amplified Biliary Tract Cancers | P2 | Completed | 87 | Open-label | ZW25 (Zanidatamab) |
| NCT07507526 A Study of Disitamab Vedotin, Tunlametinib, and PD-1 Antibody for Advanced Gastric Cancer | Gastric Adenocarcinoma | P2 | Not Yet Recruiting | 76 | Open-label | Tunlametinib+PD-1 mAb |
| NCT07290985 AACR Adaptive Biomarker-Driven Organ Preservation Trial in Gastroesophageal Adenocarcinomas | Gastroesophageal Adenocarcinoma | P2 | Not Yet Recruiting | 121 | Open-label | Tislelizumab, Leucovorin, Oxaliplatin, Fluorouracil, Zanidatamab |
| NCT03332017 A Study Comparing Obinutuzumab and BGB-3111 Versus Obinutuzumab Alone in Treating R/R Follicular Lymphoma | Relapsed/Refractory Follicular Non-Hodgkin Lymphoma | P2 | Completed | 217 | RCT, Open-label | Zanubrutinib, Obinutuzumab |
| NCT07674810 A Phase 2 Trial Of The Combination Of Zanubrutinib, Sonrotoclax, And Obinutuzumab For Patients With Treatment-Naïve Chronic Lymphocytic Leukemia | Chronic Lymphocytic Leukemia | P2 | Not Yet Recruiting | 40 | Open-label | Zanubrutinib, Obinutuzumab, Sonrotoclax |
| NCT07100938 A Study Investigating the Efficacy and Safety of BGB-45035 Versus Placebo in Adults With Moderate to Severe Active Rheumatoid Arthritis | Rheumatoid Arthritis | P2 | Terminated | 49 | RCT, Double-blind | BGB-45035, Placebo |
| NCT07682415 Zanubrutinib Induction Followed by Delayed Fixed-Duration Combination With Sonrotoclax for CLL/SLL：Stop Trial 2.0 | CLL / SLL | P2 | Not Yet Recruiting | 60 | Open-label | 12 cycles of zanubrutinib followed by 12 cycles of zanubrutinib in combination with sonrotoclax, zanubrutinib maintenance until disease progression |
| NCT04282018 Study of BGB-10188 as Monotherapy, and in Combination With Zanubrutinib, and Tislelizumab | Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | P1P2 | Completed | 97 | Open-label | BGB-10188, Zanubrutinib, Tislelizumab |
| NCT04974047 Study of Tislelizumab in Participants With Resectable Esophageal Squamous Cell Carcinoma | Resectable Esophageal Squamous Cell Carcinoma | P2 | Completed | 70 | Open-label | Tislelizumab, Paclitaxel, Cisplatin, 5-fluorouracil |
| NCT05116085 Efficacy and Safety of Tislelizumab (BGB-A317) as Neo-Adjuvant Treatment in Participants With Colorectal Cancer | Colorectal Cancer | P2 | Completed | 33 | Open-label | Tislelizumab |
| NCT06010303 A Study to Evaluate LBL-007 in Combination With Tislelizumab Plus Chemotherapy in Participants With Unresectable Locally Advanced or Metastatic Esophageal Squamous Cell Carcinoma | Esophageal Cancer, Esophageal Squamous Cell Carcinoma | P2 | Completed | 118 | RCT, Open-label | LBL-007, Tislelizumab, Chemotherapy Doublet |
| NCT06029127 A Study of Gimistotug (BGB-A445) in Combination With Other Investigational Agents in Participants With Non-Small Cell Lung Cancer | Non-Small Cell Lung Cancer | P2 | Completed | 35 | RCT, Open-label | Gimistotug, Docetaxel, BGB-15025 |
| NCT04116437 Zanubrutinib (BGB-3111) in Participants With Previously Treated B-Cell Lymphoma Intolerant of Prior Bruton Tyrosine Kinase Inhibitor (BTKi) Treatment | Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Mantle Cell Lymphoma | P2 | Completed | 96 | Open-label | Zanubrutinib |
| NCT04172246 Study of Zanubrutinib in Japanese Participants With B-Cell Malignancies | Mature B-cell Malignancies | P1P2 | Completed | 55 | Open-label | Zanubrutinib |
| NCT05577702 Efficacy, Safety, and Pharmacodynamics of Tislelizumab Monotherapy and Multiple Tislelizumab-based Immunotherapy Combinations in Participants With Resectable Non-Small Cell Lung Cancer | Non Small Cell Lung Cancer | P2 | Completed | 121 | RCT, Open-label | Tislelizumab, Ociperlimab, Alcestobart, Cisplatin, Carboplatin, Pemetrexed, Paclitaxel |
| NCT03744468 Study of Surzebiclimab (BGB-A425) and Alcestobart (LBL-007) in Combination With Tislelizumab in Advanced Solid Tumors | Locally Advanced or Metastatic Solid Tumors for Phase 1, Dose Escalation and Phase 2 Safety Lead-in, HNSCC for Phase 2 Dose Expansion | P1P2 | Completed | 147 | Open-label | Surzebiclimab, Tislelizumab, Alcestobart |
| NCT05068440 Treatment of CD79B Mutant Relapsed/Refractory Diffuse Large B-Cell Lymphoma With Bruton Tyrosine Kinase Inhibitor Zanubrutinib | Relapsed Diffuse Large B-cell Lymphoma, Refractory Diffuse Large B-cell Lymphoma | P2 | Completed | 65 | Open-label | Zanubrutinib |
| NCT05596097 Zanubrutinib in Maintenance Therapy of DLBCL Patients With Initial Remission | Diffuse Large B-cell Lymphoma (DLBCL) | P2 | Not Yet Recruiting | 15 | Open-label | Zanubrutinib |
| NCT04649385 BGB-15025 Alone and in Combination With Anti-PD-1 Monoclonal Antibody Tislelizumab in Participants With Advanced Solid Tumors | Advanced Solid Tumor | P1 | Completed | 157 | Open-label | BGB-15025, Tislelizumab, Carboplatin, Cisplatin, Pemetrexed, Oxaliplatin, Capecitabine, Paclitaxel, nab-paclitaxel |
| NCT06253195 BGB-43395 Alone or as Part of Combination Therapies in Chinese Participants With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors | Advanced Solid Tumor, Metastatic Solid Tumor | P1 | Completed | 33 | Open-label | BGB-43395, Fulvestrant, Letrozole |
| NCT05381909 A Study of BGB-24714 as Monotherapy and With Combination Therapies in Participants With Solid Tumors | Solid Tumor, Adult | P1 | Terminated | 157 | RCT, Open-label | BGB-24714, Paclitaxel, Carboplatin, Docetaxel |
| NCT07623369 A First-in-Human Study of HH160 in Patients With Advanced Solid Tumors | Solid Tumor, Non-small Cell Lung Cancer | P1 | Not Yet Recruiting | 56 | Open-label | HH160 |
| NCT06540066 A Study of BGB-B3227 Alone and in Combination With Tislelizumab in Participants With Advanced or Metastatic Solid Tumors | Advanced Cancer, Advanced Solid Tumor | P1 | Terminated | 35 | RCT, Open-label | BGB-B3227, Tislelizumab, Chemotherapy |
| NCT06906809 Effect of Phenytoin or Itraconazole on How BGB-16673 is Absorbed and Removed From the Body in Healthy Participants | Healthy Volunteers | P1 | Completed | 37 | Open-label | BGB-16673, Itraconazole, Phenytoin |
| NCT06487858 A Study of BGB-R046 as Monotherapy and in Combination With Tislelizumab in Solid Tumors | Solid Tumor | P1 | Terminated | 42 | Open-label | BGB-R046, Tislelizumab |
| NCT06342713 A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single- and Multiple-Ascending Doses and Food Effect of BGB-45035 in Healthy Participants and in Adults With Autoimmune Dermatological Diseases | Healthy Participants, Healthy Subjects | P1 | Completed | 203 | RCT, Double-blind | BGB-45035, Placebo |
| NCT06568614 An Investigational Study of BG-89894 Tablets in Participants With Advanced Solid Tumors | Advanced or Metastatic MTAP-deleted Solid Tumors | P1 | Terminated | 29 | Open-label | BG-89894 |
| NCT05935098 BGB-A3055 Alone and in Combination With Tislelizumab in Participants With Solid Tumors | Advanced Solid Tumor, Metastatic Solid Tumor | P1 | Terminated | 99 | Open-label | BGB-A3055, Tislelizumab, Chemotherapy |
| NCT06422520 A First-in-Human Study of BGB-C354 Alone and in Combination With Tislelizumab in Participants With Advanced Solid Tumors | Advanced Solid Tumor | P1 | Completed | 63 | Open-label | BGB-C354, Tislelizumab |
| NCT07005713 A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple-Ascending Doses of BGB-16673 in Adults With Chronic Spontaneous Urticaria | Chronic Spontaneous Urticaria | P1 | Completed | 34 | RCT, Double-blind | BGB-16673, Placebo |
| NCT06685718 A Study Investigating BG-60366 in Adults With Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung Cancer | Non-Small Cell Lung Cancer, Lung Cancer | P1 | Terminated | 33 | Open-label | BG-60366 |
| NCT06585488 A First-in-human Study of BGB-53038, a Pan-KRAS Inhibitor, Alone or in Combinations in Participants With Advanced or Metastatic Solid Tumors With KRAS Mutations or Amplification | Metastatic Solid Tumors, Advanced Non-squamous Non-small-cell Lung Cancer | P1 | Terminated | 47 | RCT, Open-label | BGB-53038, Tislelizumab, Cetuximab |
| NCT07141511 A Study to Investigate the Relative Bioavailability and Food Effect of a Fixed-Dose Combination Tablet Containing Zanubrutinib and Sonrotoclax (BG-71332) in Healthy Adults | Healthy Volunteers | P1 | Completed | 24 | RCT, Open-label | BG-71332, Zanubrutinib, Sonrotoclax |
| NCT03905148 Study of the Safety and Pharmacokinetics of BGB-283 (Lifirafenib) and PD-0325901 (Mirdametinib) in Participants With Advanced or Refractory Solid Tumors | Solid Tumor, Adult | P1 | Completed | 91 | Open-label | Lifirafenib, mirdametinib |